Notice: Undefined index: id in /var/www/html/wp-content/plugins/seo-by-rank-math/includes/opengraph/class-image.php on line 130
Michael J. Fox Foundation Awards an Additional Grant for Nrf2 Research
advancement of many disease conditions. This includes Parkinson’s disease (PD). The aim of this study is to determine whether the transcription factor NF-E2-related factor (Nrf2) induces antioxidant protection and phase II detoxification enzymes. Numerous studies have been published on Pubmed which suggests protection to vulnerable neurons through the NRF2/ARE pathway. This neuronal Nrf2 up-regulation study is considered an attractive therapeutic strategy for PD by the Michael J. Fox Foundation
MJF

Our original article highlighting the Michael J. Fox Foundation’s interest in NRF2 activation solutions for Parkinson’s disease met with a lot of interest, so we decided to do a follow up piece highlighting an additional study that is currently underway.

This time, the Michael J. Fox Foundation has provided a grant in its search for a Parkinson’s Disease (PD) cure to Dr. Martin Martinov, PhD. His research project is entitled “Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD”.

End-in-Mind:

As demonstrated in numerous medical studies, Oxidative stress plays a crucial role in the advancement of many disease conditions. This includes Parkinson’s disease (PD). The aim of this study is to determine whether the transcription factor NF-E2-related factor (Nrf2) induces antioxidant protection and phase II detoxification enzymes. Numerous studies have been published on Pubmed which suggests protection to vulnerable neurons through the NRF2/ARE pathway. This neuronal Nrf2 up-regulation study is considered an attractive therapeutic strategy for PD by the Michael J. Fox Foundation.

Project Description:

Gradient Biomodeling, LLC claims to have identified two new potent non-toxic Nrf2 pathway activators. Their approach claims to have higher modulators than two other NRF2 activators, BHQ and Sulforaphane. Their preliminary experiments show evidence of blood brain barrier penetration.. The main objective is to determine whether these Nrf2 activators will result in neuroprotection in  pre-clinical Parkinson’s disease conditions.

Progress Report:

Thus far the experiments prove that blood brain barrier penetration takes place. Furthermore, the compounds offer protection of dopaminergic neurons in vitro. The researchers are continuing to explore methods to improve solubility of GB822 in the gut, or to bypass the gut via alternative delivery of the compound.

Nrf2 Research Moving Forward:

Nrf2 research studies will continue to be the topic of study not just for treatment of Parkinson’s Disease, but also for the other hundreds of diseases associated with Oxidative Stress as well. The recent FDA’s approval of the NRF2 activator, Tecfidera for the treatment of MS symptoms will further the interest in using NRF2 activators to treat disease conditions. It is estimated that more than 4 million people have Parkinson’s Disease. Those impacted by the disease including patients, families, care providers and medical practitioners are interested in finding a solution to slow down or eradicate the disease.

This article is educational purposes only, consult with a medical professional to discuss your own medical conditions.

Sign Up for Our Newsletter



Read More

Oxidative Stress
New Protandim Study – International Formula Impact on Oxidative Stress
There are numerous studies about the USA Protandim formula. This one is about the International formulation.
Augusta Nrf2 Study
Augusta University Discovers How Nrf2 Activator Preserves Sight in Retinal Degeneration Model
“We are very, very pleased that we can now explore the mechanisms,”, mentioned Dr. Sylvia Smith, chair of the Department of Cellular Biology and Anatomy at the Medical College of Georgia at Augusta University and co-director of the James and Jean Culver Vision Discovery Institute at AU.
persistent fibrosis
Reversal of persistent fibrosis in aging by targeting nox4-Nrf2 redox imbalance – Sciencemag.org
This is a promising study because the current treatments of pathological and cystic fibrosis are costly and very time consuming. Persistent fibrosis in lungs of aged mice was caused by the loss of cellular redox balance. The mice in the study with low NRF2 expression had a higher incidence of progressive lung disease. Tissues from human lung samples demonstrated this same Nox4-Nrf2 imbalance.

Next Steps

Get Our Free Newsletter

View Resources

Take Our Quiz

0

PROJECTS COMPLETED

0

ACTIVE CLIENTS

0

CUPS OF COFFEE

0

HAPPY CLIENTS

TESTIMONIALS

What They Say?

SEND US YOUR FEEDBACK

Get a face-to-face appoinment with our qualified specialists

PHONE NUMBER

+ 924 888 0250

EMAIL ADDRESS

hello@spirit.health

OUR LOCATION

Crown Rd. 14b, San Diego, California


© 2021 / Spirit Health / All rights reserved

Malcare WordPress Security